-
2022-502269-13-00
4
2024-09-24
Glioma
-
2023-505655-43-00
7
2024-07-29
Metastatic neuroendocrine prostate cancer
-
2023-507325-42-00
4
2024-07-02
Alzheimer Disease psychosis
-
2023-506948-17-00
5
2024-04-05
Previously Untreated Chronic Lymphocytic Leukemia
-
2023-503925-20-00
4
2024-04-04
Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Can
-
2023-505515-21-00
5
2024-04-02
Giant Cell Arteritis
-
2023-506988-34-00
5
2024-03-27
Heart failure with mildly reduced or preserved ejection fraction and s
-
2022-501372-25-00
4
2024-01-10
Patients aged 18 years and older with relapsed or refractory FLT3 muta
-
2024-514876-41-00
9
2023-12-06
Higher-risk myelodysplastic syndromes untreated and ineligible for all
-
2023-503952-28-00
4
2023-11-13
Steroid refractory Acute Graft versus host Disease
-
2023-507672-52-00
7
2023-11-07
PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and
-
2023-503422-39-00
5
2023-10-20
Hepatocellular Carcinoma (HCC)
-
2022-500430-29-00
5
2023-10-11
Myelodysplastic Syndrome (MDS)
-
2022-500953-17-00
4
2023-03-23
Moderately to severely active ulcerative colitis
-
2024-512890-28-00
5
2023-03-20
Primary immune thrombocytopenia (ITP)
-
2023-504719-34-00
5
2023-02-21
Moderate to Severly Active Ulcerative Colitis
-
2022-501493-19-00
5
2023-02-20
metastatic Castration-Resistant Prostate Cancer (mCRPC)
-
2022-500419-38-00
5
2022-12-28
vasoplegic syndrome
-
2024-515845-40-00
5
2022-11-22
Acute kidney injury
-
2024-510947-71-00
5
2022-11-21
Chronic Myeloid Leukemia
-
2023-505628-67-00
5
2022-10-28
Relapsed and Refractory Follicular Lymphoma
-
2023-508559-37-00
5
2022-07-14
Lupus nephritis
-
2024-516403-16-00
5
2022-04-07
Adult patients with immune thrombocytopenia (ITP) with mild to severe
-
2024-515037-15-00
4
2022-03-02
PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATI